A novel polycyclic quinazoline and three quinolines alkaloids from marine-derived fungus trichoderma longibrachiatum QD01 with anti-bacterial and anti-quorum sensing activities.

A novel polycyclic quinazoline alkaloid (1) along with one new natural quinoline alkaloid (2) and two known quinoline alkaloids (3,4) were isolated from the marine-derived fungus Trichoderma longibrachiatum QD01. Structural determinations of those isolates were established by comprehensive spectroscopic analyses and literature comparison. Single-crystal X-ray diffraction analysis of novel compound verified its structure and stereochemistry, representing the first characterised crystal structure of a trimeric-type of tetrahydroquinazoline. Compound 4 exhibited potential antibacterial and anti-quorum sensing activity against C. violaceum and C. violaceum CV026. The sub-MIC of 4 observably decreased the violacein production in C. violaceum CV026 by 55% on 15 µg/mL. Furthermore, molecular docking results revealed that 4 has stronger binding interactions with CviR receptor than ligand C6-HSL with lower binding energy of -8.68 kcal/mol. Hydrogen bond and π-π interactions formed by Trp84, Tyr88, Trp111, and Phe126 were predicted to play an important role in the inhibition against C. violaceum CV026.

α-Glucosidase inhibitory effect of an anthraquinonoid produced by Fusarium incarnatum GDZZ-G2.

α-Glucosidase is the key enzyme on carbohydrate metabolism, and its bioactive inhibitors are supposed to be an effective therapeutic for type 2 diabetes mellitus. During our continuing study for discovering α-glucosidase inhibitors, a fungus GDZZ-G2 which is derived from a medicinal plant Callicarpa kwangtungensis Chun, exhibited significant inhibition on α-glucosidase. The strain was identified as Fusarium incarnatum by morphological and molecular methods. Further bioassay-guided fractionation result in six known secondary metabolites (1-6). All the compounds except 4 were isolated from F. incarnatum for the first time. Among them, an anthraquinonoid (S)-1,3,6-trihydroxy-7-(1-hydroxyethyl)anthracene-9,10-dione (compound 1) exhibited strong inhibitory effect against α-glucosidase (IC50 = 77.67 ± 0.67 µΜ), compared with acarbose (IC50 = 711.8 ± 5 µΜ). An enzyme kinetics analysis revealed that compound 1 was an uncompetitive inhibitor. Besides, docking simulations predicted that compound 1 inhibited α-glucosidase substrate complex by binding Gln322, Gly306, Thr307, and Ser329 through hydrogen-bond interactions. Our findings suggested that compound 1 can be considered a lead compound for further modifications and the development of a new effective drug candidate in the treatment of type 2 diabetes mellitus.

Discovery of mycotoxin alternariol as a potential lead compound targeting xanthine oxidase.

Xanthine oxidase (XO) catalyzes the oxidation of hypoxanthine to xanthine, which is further converted to uric acid. The excessive production or reduced excretion of the purine terminal metabolite may lead to hyperuricemia. In our ongoing search for new xanthine oxidase inhibitors, 14 endophytic fungi were isolated for the first time from a medicinal plant Callicarpa kwangtungensis Chun, and the ethyl acetate extracts of their culture filtrates were screened for XO inhibitory activity. The extract from an endophytic fungus, characterized as Alternaria alternata GDZZ-J6, exhibited the most potent inhibition of XO. Further fractionation of its secondary metabolites led to the isolation of six compounds. Among them, mycotoxin alternariol (AOH), a dibenzo-α-pyrone derivative, had strong inhibitory activity on XO, and the IC50 value was 0.23 ± 0.01 µM. The potency of XO inhibition by AOH was >12-fold higher as compared to allopurinol (2.98 ± 0.07 µM), a XO inhibitor that has been used clinically. The IC50 values of three dibenzo-α-pyrones from gut microbial metabolites of ellagic acid, urolithins A, B, and C, against XO were further compared, and their structure-activity relationships were discussed. Inhibition kinetic analysis by double-reciprocal Lineweaver-Burk plots demonstrated that AOH was an uncompetitive inhibitor. Follow-up docking studies showed that Gln957, Lys1257, and Phe1153 played an important role by forming hydrogen bonds with AOH. Our findings suggest that AOH may be used as a lead compound for further modification to develop future drug for treating hyperuricemia.